University of California, Davis

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharma

The Biotechnology Innovation Organization (BIO) has submitted comments to the US Department of the Treasury about proposed foreign investment regulations that the trade group believes will prevent for

Flagship Pioneering Founder and CEO Noubar Afeyan told Scrip earlier this year that private capital investors' interest in backing "big, bold platform ideas" in the life sciences is increasing, and